Syngene International Ltd (SYNGENE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Syngene International Ltd on NSE and BSE, with an AI summary of each filing.
Intimation of Earnings Conference call transcript for Q2 FY2027
Transcript · 02 Nov 2026, 11:15 pm
Syngene International Releases Q2 FY27 Earnings Call Transcript Syngene International has made available the transcript for its Q2 FY27 earnings conference call held on 28th Oct'26. In compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, the transcript has been uploaded to the company's official website under the investor relations financial information section.
Intimation of audio recording for Q2 FY27 post-earnings call
Audio / Video · 29 Oct 2026, 5:10 am
Syngene International Releases Audio Recording for Q2 FY27 Earnings Call Syngene International Limited has made available the audio recording of its Q2 FY27 post-earnings call conducted on 28th Oct'26. In compliance with Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, the company uploaded the recording to its official website on the same day for investor access.
Investor Presentation
Investor Presentation · 28 Oct 2026, 3:02 am
Syngene International Q2 FY27 Financial Results and Operational Highlights Syngene International reported Q2 FY27 revenue from operations of Rs 833 Cr, rising 13% QoQ but declining 9% YoY. Operating EBITDA margin stood at 18% (ex-forex hedge loss: mid-20s), while PAT before exceptional items was Rs 38 Cr, down 44% YoY. Reported PAT after exceptional items stood at Rs 32 Cr. For H1 FY27, revenue reached Rs 1,569 Cr, down 12% YoY. Operationally, Syngene signed its first manufacturing deal for the Bayview facility, secured new biologics supply contracts, and commissioned a Bengaluru Clinical Translational Sciences laboratory.
Press Release
Press Release · 28 Oct 2026, 2:10 am
Syngene Reports Q2 FY27 Financial Results with Strong Sequential Performance Syngene International posted Q2 FY27 revenue from operations of Rs 833 Cr, up 13% QoQ but down 9% YoY due to lower Zoetis revenues and forex hedge losses. Operating EBITDA rose to Rs 147 Cr with margins expanding 600 bps QoQ to 18%, while PAT reached Rs 32 Cr versus a loss of Rs 9 Cr in Q1 FY27. Key operational milestones included signing the first manufacturing agreement for the US Bayview biologics facility and securing additional contracts. CFO Deepak Jain resigned for personal reasons.
Change in Management
Change in Management · 28 Oct 2026, 1:51 am
Syngene International Announces Executive Leadership and Management Restructuring Syngene International announced key leadership changes on 27th Oct'26. CFO Deepak Jain has decided to step down to pursue outside opportunities, continuing temporarily to ensure a smooth transition. Ajay Tandon, Head of Strategy & Corporate Development, resigned effective close of business 30th Oct'26. Additionally, Subhendu Kumar (Head of Chemistry) and Priyaranjan Pattanaik (Head of Biology) transitioned from Senior Management Personnel (SMP) to Non-SMP categories effective 27th Oct'26.
Results- Financial Results for September 30, 2026.
Financial Result · 28 Oct 2026, 1:20 am
Outcome of Board Meeting
Outcome · 28 Oct 2026, 1:09 am
Syngene International Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 28 Oct 2026, 1:05 am
Syngene International Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 8,327 (-8.6% YoY | +13.1% QoQ) ■ EBITDA: 1,474 (-26.1% YoY | +62.3% QoQ) ■ EBITDA Margin (%): 17.7 (-421 bps YoY | +536 bps QoQ) ■ PAT: 322 (-52.0% YoY | Loss to Profit QoQ) ■ EPS (INR): 0.80 (-52.1% YoY | Loss to Profit QoQ)
Intimation of Conference Call for Analysts and Investors
Intimation · 28 Oct 2026, 9:00 am
Syngene Schedules Q2 FY27 Earnings Conference Call for 28th Oct'26 Syngene International Limited will host an earnings conference call for analysts and investors on 28th Oct'26 from 9:00 AM to 10:00 AM IST to discuss its financial results for the quarter ended 30th Sep'26 (Q2 FY27). The call will be conducted via Zoom. An audio recording will be made available on the company's website within 24 hours or before the next trading day, followed by the transcript within seven working days.
SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 27 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 27 Oct 2026, 5:30 am
Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the Un-Audited Standalone ....
Intimation · 27 Oct 2026, 5:30 am
Syngene International Schedules Board Meeting on 27th Oct'26 for Q2 Results Syngene International's Board of Directors is scheduled to meet on 27th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. The company will host an analyst and investor conference call on 28th Oct'26. In accordance with insider trading regulations, the trading window for dealing in company securities remains closed from 1st Oct'26 until the close of trading hours on 29th Oct'26.
Intimation of cancellation of meeting with Analyst/Institutional Investors
Intimation · 24 Sept 2026, 5:21 pm
Syngene International Cancels Analyst Meeting with Bajaj AMC Syngene International Limited announced the cancellation of its scheduled investor meeting with Bajaj AMC, which was originally slated to take place on Thursday, 24th Sep'26. The company submitted the regulatory update to the BSE and NSE in continuation of its prior disclosure dated Ref: Syn/CS/SE/Reg 30/2026-27/Sept/05.
Resignation of Mr. Pramuch Goel as Head Corporate Affairs & Communications and a member of Executive Committee (Senior Management Personnel) of the Company w.e.f. the close of business ....
Change in Management · 22 Sept 2026, 4:26 am
Syngene International Announces Resignation of Senior Management Personnel Pramuch Goel Syngene International Limited announced that Mr. Pramuch Goel, Head of Corporate Affairs & Communications and an Executive Committee member (Senior Management Personnel), has resigned from the company to pursue other career opportunities outside the organization. His cessation is effective from the close of business hours on 21st Sep'26, following his formal resignation letter tendered on 15th Sep'26.
Intimation of Schedule of Meeting with Analyst/Institutional Investor
Intimation · 21 Sept 2026, 11:18 pm
Syngene International Schedules One-on-One Investor Meeting With Bajaj AMC Syngene International Limited will host a one-on-one meeting with Bajaj AMC on 24th Sep'26 at 12:00 PM IST. The interaction will be conducted virtually from Bengaluru. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the scheduled discussion.
Intimation of Schedule of Meeting with Analyst/Institutional Investor
Intimation · 13 Sept 2026, 1:56 am
Syngene International Schedules Investor Meeting at Kotak Healthcare Forum Syngene International Limited has scheduled an in-person analyst and institutional investor meeting on 17th Sep'26 at 09:00 AM IST in Mumbai. The company will participate in group and one-on-one sessions during the Healthcare Forum 2026 organized by Kotak. Management confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the interactions.
Intimation of Schedule of Meeting with Analyst/Institutional Investor
Intimation · 12 Sept 2026, 12:50 am
Syngene International Schedules One-on-One Investor Meeting with True Beacon PMS Syngene International Limited will host a virtual one-on-one meeting with True Beacon PMS on 17th Sep'26 at 12:00 PM IST from Bengaluru. The interaction will be conducted pursuant to Regulation 30(6) of SEBI LODR Regulations, 2015. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the session.
Communication regarding remittance of final dividend for the FY 2025-26
Dividend · 10 Sept 2026, 10:53 pm
Syngene International Dispatches FY26 Final Dividend Remittance Communication Syngene International has issued communications to shareholders regarding the remittance of its final dividend for FY26. Following approval at the AGM on 29th Jul'26, the company is remitting a dividend of 12.50%, equivalent to Rs 1.25 per equity share (face value Rs 10 each), to eligible shareholders who held shares as of the record date on 26th Jun'26. Disbursements are being processed via electronic modes or warrants, with KFin Technologies acting as the Registrar and Share Transfer Agent.
Grant of Performance Share Units under Syngene Long Term Incentive Performance Share Plan (PSP) 2023 ("Plan")
Others (Uncategorized) · 02 Sept 2026, 4:59 am
Intimation of Schedule of Investor/Analyst Meeting with Goldman Sachs Asia Leaders Conference 2026
Intimation · 25 Aug 2026, 10:04 pm
Syngene Schedules Investor Meetings at Goldman Sachs Conference Syngene International will participate in the Goldman Sachs Asia Leaders Conference 2026 in Hong Kong from Aug 31 to Sep 1, '26. The management will hold in-person group and one-on-one meetings with analysts and institutional investors. Syngene has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be disclosed during these interactions. The meeting is a standard investor relations engagement.
Intimation of investment in Ampin C&I Power Twelve Private Limited
Others (Uncategorized) · 24 Aug 2026, 11:36 pm
Syngene to Acquire Stake in Ampin C&I for Renewable Power Syngene International will invest ₹2.52 crore to acquire a stake in renewable energy firm Ampin C&I Power Twelve Private Limited. The investment involves subscribing to 25,20,000 equity shares at ₹10 each. This will initially result in a 12.44% holding, which will subsequently be maintained at a minimum of 7.93% on a fully diluted basis. The cash acquisition, part of a power purchase agreement, aligns with Syngene's goals to enhance green energy use, reduce energy costs, and lower its carbon footprint. The transaction is not a related-party deal.
Intimation of Investor call schedule with Entrust Family Office
Intimation · 24 Aug 2026, 8:24 pm
Syngene Schedules One-on-One Meeting with Entrust Family Office Syngene International announced a virtual one-on-one meeting with Entrust Family Office scheduled for 12:00 PM IST on 28 Aug'26. The company has confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during this engagement. The meeting will be held virtually with the venue designated as Bangalore.
Intimation of Schedule of Meeting with Analyst/Institutional Investor on August 13, 2026 and August 14, 2026.
Intimation · 10 Aug 2026, 10:46 pm
Syngene Schedules Investor Meetings at Emkay Confluence 2026 Syngene International Ltd. has scheduled in-person group and one-on-one meetings with analysts and institutional investors on Aug 13 and Aug 14, '26. The meetings will take place in Mumbai as part of the "Emkay Confluence 2026" conference, organized by Emkay Global. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during these interactions. This event provides an opportunity for engagement with the investment community.
Intimation of Earnings Conference call transcript for Q1 FY2027
Transcript · 07 Aug 2026, 12:16 am
Syngene Publishes Q1 FY27 Earnings Call Transcript Syngene International announced on 06 Aug'26 the availability of its Q1 FY27 earnings conference call transcript. The call, which provides detailed insights into the company's quarterly performance and management outlook, was originally held on 30 Jul'26. The transcript is now accessible on the company's official website for investor review.
Scrutinizer''s Report and voting results of 33rd Annual General Meeting
Annual General Meeting · 31 Jul 2026, 7:53 pm